de Zeeuw D - Search Results

1

Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.

Haverdings RG, Haas M, Navis GJ, van Loenen-Weemaes AM, Meijer DK, de Zeeuw D, Moolenaar F. Haverdings RG, et al. Among authors: de zeeuw d. Br J Pharmacol. 2003 Feb;138(4):531. doi: 10.1038/sj.bjp.0705183. Br J Pharmacol. 2003. PMID: 12622114 Free PMC article. No abstract available.

2

Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.

Kok RJ, Haverdings RF, Grijpstra F, Koiter J, Moolenaar F, de Zeeuw D, Meijer DK. Kok RJ, et al. Among authors: de zeeuw d. J Pharmacol Exp Ther. 2002 Jun;301(3):1139-43. doi: 10.1124/jpet.301.3.1139. J Pharmacol Exp Ther. 2002. PMID: 12023548

3

Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.

Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, de Zeeuw D, Meijer DK. Kok RJ, et al. Among authors: de zeeuw d. J Pharmacol Exp Ther. 1999 Jan;288(1):281-5. J Pharmacol Exp Ther. 1999. PMID: 9862782

4

Enalapril and the kidney: renal vasodilation and natriuresis due to the inhibition of angiotensin II formation.

Navis GJ, de Zeeuw D, de Jong PE. Navis GJ, et al. Among authors: de jong pe, de zeeuw d. J Cardiovasc Pharmacol. 1986;8 Suppl 1:S30-4. J Cardiovasc Pharmacol. 1986. PMID: 2422491

5

Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat.

Haas M, Moolenaar F, Meijer DK, de Jong PE, de Zeeuw D. Haas M, et al. Among authors: de jong pe, de zeeuw d. Clin Sci (Lond). 1998 Nov;95(5):603-9. doi: 10.1042/cs0950603. Clin Sci (Lond). 1998. PMID: 9791047

6

D2 -like receptor stimulation decreases effective renal plasma flow and glomerular filtration rate in spontaneously hypertensive rats.

Marcel de Vries PA, de Jong PE, de Zeeuw D, Navis GJ. Marcel de Vries PA, et al. Among authors: de jong pe, de zeeuw d. J Cardiovasc Pharmacol. 2002 Jul;40(1):35-42. doi: 10.1097/00005344-200207000-00005. J Cardiovasc Pharmacol. 2002. PMID: 12072575

7

Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats.

de Vries PA, Navis G, de Jong PE, de Zeeuw D, Kluppel CA. de Vries PA, et al. Among authors: de jong pe, de zeeuw d. J Cardiovasc Pharmacol. 1999 Aug;34(2):191-8. doi: 10.1097/00005344-199908000-00003. J Cardiovasc Pharmacol. 1999. PMID: 10445669

8

Low-molecular-weight proteins as carriers for renal drug targeting.

Franssen EJ, Moolenaar F, de Zeeuw D, Meijer DK. Franssen EJ, et al. Among authors: de zeeuw d. Contrib Nephrol. 1993;101:99-103. Contrib Nephrol. 1993. PMID: 8467694 No abstract available.

9

ACE-inhibitors: panacea for progressive renal disease.

Navis G, de Zeeuw D, de Jong PE. Navis G, et al. Among authors: de jong pe, de zeeuw d. Lancet. 1997 Jun 28;349(9069):1852-3. doi: 10.1016/s0140-6736(97)22026-x. Lancet. 1997. PMID: 9217751 No abstract available.

10

Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.

van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D. van der Kleij FG, et al. Among authors: de jong pe, de zeeuw d. Kidney Int Suppl. 1997 Dec;63:S23-6. Kidney Int Suppl. 1997. PMID: 9407415 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

659 results

Search Page

Filters